Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Novartis to acquire Excellergy for $2 billion
PUBLIC · NVSMar 27, 2026•4 months ago
Acquiring Company
Novartis Pharma AG
Acquired Company
Excellergy
SwitzerlandPalo AltoBiotechnologyHealth CarepharmaceuticalsBiotechnologyHealth Care
Description
Excellergy, Inc. has announced its acquisition by Novartis for up to $2 billion. This acquisition unites Excellergy's novel allergy therapeutics with Novartis's development expertise. Exl-111, a trifunctional effector cell response inhibitor, is currently in Phase 1 trials. The transaction is subject to customary closing conditions.
Company Information
Company
Novartis Pharma AG
Location
2 Fabrikstrasse
Switzerland
About
Novartis is an innovative medicines company focused on reimagining medicine to extend patient lives. With over 30 years in oncology, it aims to impact cancer care significantly. The company has a broad research and development portfolio. Novartis's goal is to provide pioneering cancer treatments through technology and patient-centered research.
Switzerland
Palo AltoBiotechnologyHealth CarepharmaceuticalsBiotechnologyHealth Care